{
  "meta": {
    "timestamp": "2025-01-06T12:28:16.634944",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Exact Sciences Corp",
      "symbol": "EXAS",
      "analysis": {
        "historical": {
          "risk_score": 60,
          "key_risks": [
            "Legal and regulatory challenges, including patent infringement lawsuit and FDA scrutiny",
            "Reimbursement and pricing pressures, particularly reliance on Medicare and other insurers",
            "High dependence on Cologuard for revenue, making the company vulnerable to product-specific risks",
            "Intense competition in the diagnostic industry, threatening market share and margins"
          ],
          "controversies": [
            "Patent infringement lawsuit against Geneoscopy",
            "FDA warning letter regarding regulatory approval for noninvasive colon cancer screening test"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical concerns related to false positives and unnecessary diagnostic procedures",
            "Public health campaigns to promote colon cancer screening, enhancing brand recognition"
          ],
          "governance_issues": [
            "Regulatory scrutiny and compliance challenges with FDA requirements"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Court Ruling Enables Exact Sciences to Proceed with Lawsuit against ...",
              "snippet": "Company asserts that Geneoscopy will infringe patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis., May 21, 2024 \u2014 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy's (defendant) motion to dismiss a patent infringement lawsuit filed by ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958338+00:00",
              "published_date": null,
              "source_hash": "2a183f07b6490af80c4d8492dcd5e442"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation - Court Ruling Enables Exact Sciences to ...",
              "snippet": "About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard\u00ae and Oncotype\u00ae tests, Exact Sciences is investing in its pipeline to develop innovative solutions ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958437+00:00",
              "published_date": null,
              "source_hash": "c0d45d5eb7825ff6b258deb053a5514c"
            },
            {
              "url": "",
              "title": "Court Ruling Enables Exact Sciences to Proceed with Lawsuit against ...",
              "snippet": "MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958455+00:00",
              "published_date": null,
              "source_hash": "dbb9933dec7a61ae91ad7586d151dfdc"
            },
            {
              "url": "",
              "title": "Rosen v. Exact Sciences Corporation et al, No. 8:2019cv01526 - Justia Law",
              "snippet": "Exact Sciences Corporation et al, No. 8:2019cv01526 - Document 102 (M.D. Fla. 2023) case opinion from the Middle District of Florida US Federal District Court. ... The plaintiffs do not dispute that the SuperCertificate 4 program goes unmentioned by name in the plaintiffs' amended complaint (Doc. 23). The plaintiffs instead argue the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958466+00:00",
              "published_date": null,
              "source_hash": "f53edafe3f50a9947ae0d50f961c1e29"
            },
            {
              "url": "",
              "title": "Exact Sciences Agrees To Pay $13.75 Million To Resolve Kickback Case ...",
              "snippet": "The Defendants in the case were Exact Sciences Corporation and Exact Sciences Laboratories, LLC (\"Exact Sciences\"). Exact Sciences is a laboratory company that manufactures, markets, and sells a colon cancer screening test called \"Cologuard\" throughout the United States. Cologuard is an at-home screening test that Exact Sciences claims ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958478+00:00",
              "published_date": null,
              "source_hash": "078e58033c6c0159e3c7780aa79485ae"
            },
            {
              "url": "",
              "title": " COMPLAINT FOR PATENT INFRINGEMENT OVERVIEW OF THE ACTION - Exact Sciences",
              "snippet": "Exact Sciences is a corporation organized and existing under the laws of the State of Delaware having a place of business at 5505 Endeavor Lane, Madison, WI 53719. Exact Sciences is the assignee and owner of the '781 Patent. 19. On information and belief, Geneoscopy is a corporation organized and existing",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958489+00:00",
              "published_date": null,
              "source_hash": "2ebd0a64077e8ea43f3c79664408ea0e"
            },
            {
              "url": "",
              "title": "Exact Scis. Corp. v. Blue Cross & Blue Shield of N.C. - Casetext",
              "snippet": "N. Carlton Tilley, Jr. Senior United States District Judge. MEMORANDUM OPINION AND ORDER. Plaintiffs Exact Sciences Corporation (\"Exact Sciences\") and Exact Sciences Laboratories, LLC (\"Exact Labs\") (collectively referred to as \"Exact\") have sued Defendant Blue Cross and Blue Shield of North Carolina (\"BCBS-NC\") for BCBS-NC's alleged failure to pay Exact for the performance of its proprietary ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958500+00:00",
              "published_date": null,
              "source_hash": "ac916c2d200ebb7384c21e33c84c3bb4"
            },
            {
              "url": "",
              "title": "Sullivan v. Exact Scis. Corp., Civil Action 3:22-116 - Casetext",
              "snippet": "In reaching this finding, the Court stresses that it was Mr. Conroy who: (1) was the primary decisionmaker involved in creating Exact Sciences' vaccine requirement, (2) announced that employees would be required to be vaccinated by the deadline, (3) and denied Ms. Sullivan's accommodation request, leading to her termination. (ECF No. 22 at \u00b6\u00b6 16-18, 52-53).",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958511+00:00",
              "published_date": null,
              "source_hash": "a9134e8efcfaf45a3f37bf196b65086e"
            },
            {
              "url": "",
              "title": "Geneoscopy Files Counterclaims Against Exact Sciences",
              "snippet": "Also on June 28, Exact Sciences filed a motion for a preliminary injunction against Geneoscopy. The motion, filed seven months after the initial suit, is based on two related patent infringement claims, which are limited to specific methods of collecting and processing stool samples. Geneoscopy believes that Exact Sciences' patent suit and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958523+00:00",
              "published_date": null,
              "source_hash": "d2bfc8293874c243323ba268aca9653a"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation | BBB Complaints - Better Business Bureau",
              "snippet": "View complaints of Exact Sciences Corporation filed with BBB. BBB helps resolve disputes with the services or products a business provides.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:43.958533+00:00",
              "published_date": null,
              "source_hash": "97801826d83e49e44e0fcf2d08a884c5"
            },
            {
              "url": "",
              "title": "Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)",
              "snippet": "Exact Sciences is also likely to renegotiate commercial ... William Blair writes that the determinations effectively raise reimbursement by 16% versus the current Medicare rate for the first ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:47.285655+00:00",
              "published_date": "2024-11-26T13:24:00+00:00",
              "source_hash": "bca0b7f17d1798f46381fa0c7765f713"
            },
            {
              "url": "",
              "title": "Exact Sciences stock outlook improves with Cologuard Plus launch and Medicare reimbursement",
              "snippet": "The firm's analysis indicates that the launch of Cologuard Plus in late Q1 2025 or early Q2 2025 could significantly impact revenue, with a projected reimbursement rate of $592 for Medicare Fee ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp reimbursement disputes",
              "retrieved_at": "2025-01-06T19:27:47.285795+00:00",
              "published_date": "2024-11-26T12:51:00+00:00",
              "source_hash": "968eaa57c23005909d4daa0b7e8e3423"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation - New Prospective Data Demonstrate Low False ...",
              "snippet": "Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research , that expands on foundational clinical study findings to include a key younger population. Study results show that ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695211+00:00",
              "published_date": null,
              "source_hash": "013cd1ae54ce35180e88c4b8dbc9dbef"
            },
            {
              "url": "",
              "title": "Beware: an insurance company colon cancer screening scam that ... - Reddit",
              "snippet": "There are several versions of this kit from Cologuard (which looks for cancer DNA in the stool) to this test \"OC-Auto\" which is just an extremely sensitive test for hemoglobin/blood). ... prior to testing or that should cause someone to delay testing like stopping the medications that are known to cause false positives or any of the conditions ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695282+00:00",
              "published_date": null,
              "source_hash": "795a537e2fd20021f3b525bfcdcd1963"
            },
            {
              "url": "",
              "title": "Next Generation Cologuard Test Demonstrates 94 Percent ... - Exact Sciences",
              "snippet": "MADISON, Wis., June 20, 2023 - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. The results show that next-generation Cologuard \u00ae met all study endpoints and improved every top-line metric, including a 30 percent lower false positive rate, when compared to DeeP-C, the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695295+00:00",
              "published_date": null,
              "source_hash": "9c77ba5f2957d4310b29ca7931ce7e3c"
            },
            {
              "url": "",
              "title": "New Prospective Data Demonstrate Low False-Positive Rate for Screening ...",
              "snippet": "Cologuard was approved by the FDA in August 2014, and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial in adults 50 years of age or older were ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695306+00:00",
              "published_date": null,
              "source_hash": "3edf0fea78433621899c130e8f181873"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation - FDA Approves Exact Sciences' Cologuard ...",
              "snippet": "Cologuard Plus\u2122 test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test Company expects to launch Cologuard Plus test with Medicare coverage and guideline inclusion in 2025 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695314+00:00",
              "published_date": null,
              "source_hash": "5e3a0032a56367822feccf98b5a3dbe6"
            },
            {
              "url": "",
              "title": "FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New ...",
              "snippet": "MADISON, Wis., October 04, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695324+00:00",
              "published_date": null,
              "source_hash": "c0a040f35e99155215a040083c909b93"
            },
            {
              "url": "",
              "title": "Next-Generation Cologuard Improves Colorectal Cancer Detection, False ...",
              "snippet": "The findings from the 26,000-plus participant trial that spanned late 2019 to early 2023 provides validation for the utility and accuracy of the latest iteration of Cologaurd, with Paul Limburg, MD, MPH, chief medical officer of Screening for Exact Sciences calling it \"a new standard in non-invasive colorectal cancer and precancer detection.\" 2",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695332+00:00",
              "published_date": null,
              "source_hash": "17aa32befbaf755e33d043a53d642c8e"
            },
            {
              "url": "",
              "title": "FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New ...",
              "snippet": "\"Cologuard Plus sets a new performance standard in non-invasive colorectal cancer screening for patients,\" said Kevin Conroy, Chairman and CEO of Exact Sciences. \"Cologuard Plus detects cancers and precancerous polyps with even greater sensitivity than Cologuard while reducing false positives by more than 30 percent.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695339+00:00",
              "published_date": null,
              "source_hash": "7e38db25f5020c2a71078e9978428708"
            },
            {
              "url": "",
              "title": "Exact Sciences Presents Data Showing Improved Accuracy of Second ...",
              "snippet": "MADISON, Wis., Jan. 18, 2022\u2014 Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at specificity of 92.4% for negative samples confirmed by colonoscopy.Subgroup analyses showed 83.3% sensitivity for high-grade dysplasia, the most dangerous ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695347+00:00",
              "published_date": null,
              "source_hash": "90762c53e8002ab5efd7a11b41093896"
            },
            {
              "url": "",
              "title": "Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy",
              "snippet": "Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test. MADISON, Wis., November 17, 2023 \u2014 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:49.695357+00:00",
              "published_date": null,
              "source_hash": "25a72a6a8fcf3aaac960bc993595d2cd"
            },
            {
              "url": "",
              "title": "Exact Sciences: Profitability Remains Elusive",
              "snippet": "Exact Sciences Corporation ... Cologuard offering, the next-generation product Cologuard Plus received FDA approval in October 2024 after demonstrating greater sensitivity and 30% fewer false ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:52.246491+00:00",
              "published_date": "2024-12-13T16:01:00+00:00",
              "source_hash": "e565e0b8b3d8dfd95a25dc747fdc1e7d"
            },
            {
              "url": "",
              "title": "Exact Sciences",
              "snippet": "EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:52.246594+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "9c3c999895882ec4d614b2d89cc59c73"
            },
            {
              "url": "",
              "title": "Exact Sciences and Lil Jon Partner on \"Get Low #2\" Campaign to Encourage Colon Cancer Screening",
              "snippet": "Exact Sciences Corp., a leading provider ... study of patients 50 and older. The Cologuard test performance in repeat testing has not been evaluated. The Cologuard test result should be interpreted with caution. A positive test result does not confirm ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:52.246622+00:00",
              "published_date": "2024-12-02T09:30:00+00:00",
              "source_hash": "cae0d889f9c89b0006acdfccb017794b"
            },
            {
              "url": "",
              "title": "Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)",
              "snippet": "Cologuard Plus secures 16% pricing rises from Centers for Medicare & Medicaid Services. Exact Sciences is also likely ... highlights that the update is a positive outcome for the company, as ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Exact Sciences Corp Exact Sciences Corp Cologuard false positives controversy",
              "retrieved_at": "2025-01-06T19:27:52.246647+00:00",
              "published_date": "2024-11-26T13:24:00+00:00",
              "source_hash": "1e41430bd5e8415828d0ac8c4552381e"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now",
              "snippet": "In the latest quarter, Exact Sciences Corporation (NASDAQ:EXAS) showed encouraging results for its blood-based test with 88% cancer sensitivity and received FDA approval for Cologuard Plus ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:58.289357+00:00",
              "published_date": "2024-11-20T00:10:00+00:00",
              "source_hash": "f9cc7141846a107b8e15a51f1266697f"
            },
            {
              "url": "",
              "title": "Exact Sciences says gets warning letter from FDA | Reuters",
              "snippet": "Exact Sciences Corp  said on Tuesday it received a warning letter from U.S. regulators, who believe the company's noninvasive colon cancer screening test requires regulatory approval.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914530+00:00",
              "published_date": null,
              "source_hash": "840a44c71c42519464d62550a1e5b14c"
            },
            {
              "url": "",
              "title": "Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight",
              "snippet": "Exact Sciences Corporation (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests, has recently filed its 10-Q report on November 5, 2024. The company, known for its noninvasive ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914647+00:00",
              "published_date": null,
              "source_hash": "c63f9b404bce8b33f394a4f1181cea60"
            },
            {
              "url": "",
              "title": "Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)",
              "snippet": "Included was a final decision related to CMS pricing for Exact Sciences Corp's (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914664+00:00",
              "published_date": null,
              "source_hash": "694e36017aa26436132d6203c08e8e28"
            },
            {
              "url": "",
              "title": "Press Releases - Exact Sciences",
              "snippet": "Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum \u2014 starting with familial risk. ... pending approval. Read more. Pipeline; Publications; Clinical studies; Grants; Exact Labs; ... Exact Sciences Corporation 5505 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914678+00:00",
              "published_date": null,
              "source_hash": "9e3d8bb902450a233838395b7a250550"
            },
            {
              "url": "",
              "title": "Exact Sciences says gets warning letter from FDA | Reuters",
              "snippet": "Exact Sciences Corp <EXAS.O> said on Tuesday it received a warning letter from U.S. regulators regarding its colon cancer screening product.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914699+00:00",
              "published_date": null,
              "source_hash": "9a488a98125e7b04b36cc69926592921"
            },
            {
              "url": "",
              "title": "Exact Sciences Pipeline Intact but Profits Remain Several ... - Morningstar",
              "snippet": "Though our outlook on Exact Sciences is uncertain, with significant competition expected to enter the early-screening market over the next decade, we think Exact's early-entrant status in pan ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914712+00:00",
              "published_date": null,
              "source_hash": "83de2a345de95af27dc7748d9c01681e"
            },
            {
              "url": "",
              "title": "Exact Sciences Announces Third-Quarter 2024 Results",
              "snippet": "MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023. \"The Exact Sciences' team is helping eradicate cancer while strengthening our platform and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914724+00:00",
              "published_date": null,
              "source_hash": "2ec30ef0f8238436bc20016b845d67b5"
            },
            {
              "url": "",
              "title": "Exact Sciences Corp | Reuters",
              "snippet": "The latest international Exact Sciences Corp news and views from Reuters - one of the world's largest news agencies ... detect cancer that starts in the colon or rectum got an approval from the U ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914739+00:00",
              "published_date": null,
              "source_hash": "5b1794d7aa32cfd6d96ce594790c9451"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Continued approval of the PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. This report, identified as \"Annual Report\" and bearing the applicable PMA reference number, should be submitted to the address below.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914750+00:00",
              "published_date": null,
              "source_hash": "ec7ac4ee5a2421035ffad04827fe0643"
            },
            {
              "url": "",
              "title": "Exact Sciences' FDA Approval Drives Stock, Investors Waiting for More ...",
              "snippet": "Regulatory approval for a breakthrough technology in testing for cancer is driving up shares of Exact Sciences Corp. The company received FDA approval to sell the first noninvasive DNA screening ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:55.914762+00:00",
              "published_date": null,
              "source_hash": "75ee1b066352990b58680af7aba407a2"
            },
            {
              "url": "",
              "title": "Exact Sciences: Profitability Remains Elusive",
              "snippet": "Exact Sciences Corporation is a Madison ... the next-generation product Cologuard Plus received FDA approval in October 2024 after demonstrating greater sensitivity and 30% fewer false positives ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:58.289203+00:00",
              "published_date": "2024-12-13T16:01:00+00:00",
              "source_hash": "0d37559ccdd2964aa2b4605e4672a076"
            },
            {
              "url": "",
              "title": "Exact Sciences Corporation (EXAS)",
              "snippet": "Included was a final decision related to CMS pricing for Exact Sciences Corp's (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:58.289303+00:00",
              "published_date": "2025-01-02T23:09:00+00:00",
              "source_hash": "f29f87b49b0870b6674c86d397936bb4"
            },
            {
              "url": "",
              "title": "Exact Sciences Corp.",
              "snippet": "Source: FactSet Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet Markets Diary: Data on U.S ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:58.289333+00:00",
              "published_date": "2022-06-08T04:10:00+00:00",
              "source_hash": "b031b858ecebe8a21c70f1d76148815b"
            },
            {
              "url": "",
              "title": "Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights",
              "snippet": "Exact Sciences Corporation (EXAS ... Key developments include FDA approval for the Cologuard Plus\u2122 test and notable data on its blood-based colorectal cancer screening test, positioning Exact ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Exact Sciences Corp Exact Sciences Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T19:27:58.289381+00:00",
              "published_date": "2024-11-06T20:01:00+00:00",
              "source_hash": "8429d7a96b9e7ca26807daa0c981e932"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Exact Sciences Corp reimbursement disputes",
              "rationale": "Investigate potential legal or financial issues related to insurance reimbursement rates and policies",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "Exact Sciences Corp Cologuard false positives controversy",
              "rationale": "Explore public perception and trust issues related to the accuracy of Cologuard tests",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "Exact Sciences Corp regulatory approval delays",
              "rationale": "Examine challenges and delays in obtaining regulatory approvals for new diagnostic tests",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:28:16.634956",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}